Literature DB >> 11073352

Elderly heart failure patients with drug-induced serious hyperkalemia.

D Vanpee1, C H Swine.   

Abstract

We report four cases of hyperkalemia induced by the association of spironolactone with ACE inhibitor in geriatric patients. Over a period of one year, four elderly patients treated for congestive heart failure with this association were admitted to the Geriatric Ward with serious hyperkalemia. These occurrences represented one third of all-cause severe hyperkalemia cases admitted during this one-year period. A common observation in our cases was that the dose of spironolactone employed far exceeded the recommended dosages. These cases illustrate that spironolactone dosage must be kept low in the setting of chronic congestive heart failure treatment, as well as the need for close monitoring of frail elderly patients who are given this combination.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11073352     DOI: 10.1007/BF03339853

Source DB:  PubMed          Journal:  Aging (Milano)        ISSN: 0394-9532


  3 in total

1.  Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases.

Authors:  Eike Wrenger; Regina Müller; Michael Moesenthin; Tobias Welte; Jürgen C Frölich; Klaus H Neumann
Journal:  BMJ       Date:  2003-07-19

2.  Heart failure therapy in diabetic patients-comparison with the recent ESC/EASD guideline.

Authors:  Frank Edelmann; Rolf Wachter; Hans-Dirk Düngen; Stefan Störk; Annette Richter; Raoul Stahrenberg; Till Neumann; Claus Lüers; Christiane E Angermann; Felix Mehrhof; Götz Gelbrich; Burkert Pieske
Journal:  Cardiovasc Diabetol       Date:  2011-02-08       Impact factor: 9.951

3.  A randomised, controlled, double-blind, cross-over pilot study assessing the effects of spironolactone, losartan and their combination on heart rate variability and QT dispersion in patients with chronic heart failure.

Authors:  A Shehab; A A Elnour; A D Struthers
Journal:  Cardiovasc J Afr       Date:  2008 Nov-Dec       Impact factor: 1.167

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.